Parexel closes San Diego office, axes 3 and offers others work-from-home roles

Parexel building
Parexel shut down a San Diego office back in April. (Parexel)

Parexel shut down a San Diego office back in April, and three workers were axed while 37 others were offered work-from-home jobs.

This happened because there wasn’t enough use of the space. The company explained to FierceCRO: “In April 2019, Parexel closed our physical office in San Diego based on a review that showed low employee utilization of the available space over an extended period of time.

“Parexel provided our 37-local office-based employees flexible work-from-home arrangements to maintain our local presence while aligning our practices more closely with how our employees work today. A small number of roles, specifically our local Facilities and IT support, were eliminated based on the office closure.”

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The closure was first made public in a recent WARN notice from California.

RELATED: Parexel nabs high-profile former FDA staffers, beefing up its regulatory offerings

This comes after fellow biopharma services company and rival Charles River Laboratories made a similar decision, cutting 24 employees from its San Diego site earlier this year. This also came out of a WARN notice, with the cuts confirmed to FierceCRO back in April, and staffers were relocated to a different site.

Suggested Articles

VistaGen responded to the failure of the ketamine-line drug by vowing to review all the data before deciding on next steps.

Exicure is set to receive $25 million upfront to apply its spherical nucleic acid technology to two collaborative programs. 

Dewpoint Therapeutics is teaming up with Bayer on new drugs for a pair of neglected fields: heart disease and women’s health.